Project Grant K99HL188356
Award Date 7/21/26
Completion Date 5/31/28
Dollars Obligated $131K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94158, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health within the Department of Health and Human Services, awarded J. David Gladstone Institutes $925,796 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop machine learning methods for identifying noncoding genetic variants that cause congenital heart disease. Gladstone will create a deep learning toolkit to predict how rare and de novo noncoding...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $162,391 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define mechanisms of cardiovascular dysfunction in Down syndrome and identify therapeutic candidates. The research uses vascularized cardiac organoids derived from human pluripotent stem cells, integrated with single-cell multi-omics, high-throughput screening, and artificial intelligence-driven data mining to...
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $1,585,727 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epigenomic mechanisms of cardiac fibrosis and heart failure. The project tests the hypothesis that the transcriptional regulator Meox1 functions as a key driver of fibroblast activation, myocardial fibrosis, and heart failure pathogenesis, leveraging novel genetic mouse models, cell lines, and...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $124,688 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode the gene regulatory network of mammalian cardiac maturation. The award funds a K99/R00 research project investigating the molecular mechanisms driving postnatal cardiac development. During the K99 phase, the recipient will characterize epigenomic changes in the mouse heart during...
- The National Heart, Lung, and Blood Institute awarded Boston Children's Hospital $144,817 on May 8, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund a K99/R00 Project Grant investigating the molecular mechanisms of congenital heart disease through endocardial signaling regulation. The funded research identifies sphingosine-1-phosphate receptor 1 (S1PR1), a G protein-coupled receptor, as a key regulator of Notch1 signaling during heart development. The investigator...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the J. David Gladstone Institutes $1,569,656 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate chromatin regulation of immune cells in myocardial inflammation, with performance through May 31, 2030. The project elucidates BRD4-mediated chromatin and gene regulatory networks controlling monocyte differentiation and macrophage function during myocardial infarction, with the goal of...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $768,912 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify and validate genetic variants associated with cardiac differentiation and congenital heart disease. The research integrates artificial intelligence with genome engineering to discover intrinsic gene regulatory networks governing heart development. Stanford will employ a base-resolution neural network...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $779,600 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the developmental mechanisms that direct cardiac cell diversification and left ventricle morphogenesis. The research employs single-cell transcriptomic analyses and lineage tracing in mouse embryos to define the gene regulatory networks controlling how diverse cardiac cell types emerge from...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, operating as Lawrence Berkeley National Laboratory, $2,057,231 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to map and decode the enhancer landscape of human heart development. The award funds a research project that creates a single-cell enhancer atlas of the developing human heart by integrating genome-wide single-cell multiome data from critical...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of California, San Diego $168,795 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on proteostasis in hematopoietic stem cell development. The project, titled "Proteostasis in Hematopoietic Stem Cell Development," addresses dysfunction in inherited bone marrow failure syndromes by investigating protein homeostasis disruption in...